Analysts Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.63

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been given a consensus rating of “Buy” by the eight ratings firms that are covering the company, Marketbeat reports. Eight analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $6.63.

Several research firms have recently issued reports on TSHA. Canaccord Genuity Group lifted their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, February 27th.

Taysha Gene Therapies Stock Down 1.1 %

Taysha Gene Therapies stock opened at $1.72 on Tuesday. The firm has a market capitalization of $352.60 million, a P/E ratio of 2.73 and a beta of 0.91. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a twelve month low of $1.19 and a twelve month high of $4.32. The stock’s fifty day simple moving average is $1.66 and its 200-day simple moving average is $1.94.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The firm had revenue of $2.02 million for the quarter, compared to analyst estimates of $2.05 million. As a group, equities analysts expect that Taysha Gene Therapies will post -0.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Avoro Capital Advisors LLC grew its holdings in Taysha Gene Therapies by 7.2% during the 4th quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company’s stock valued at $34,600,000 after buying an additional 1,349,999 shares during the last quarter. Octagon Capital Advisors LP increased its position in Taysha Gene Therapies by 128.6% during the 4th quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company’s stock worth $18,078,000 after purchasing an additional 5,877,778 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Taysha Gene Therapies by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company’s stock valued at $15,409,000 after purchasing an additional 641,305 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of Taysha Gene Therapies in the fourth quarter valued at approximately $8,650,000. Finally, Geode Capital Management LLC grew its stake in Taysha Gene Therapies by 0.3% in the 4th quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company’s stock worth $6,182,000 after acquiring an additional 9,591 shares during the period. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.